Gaithersburg-based Sigma-Tau Pharmaceuticals Inc. said Thursday it has won Food and Drug Administration approval for Cystaran, which treats a symptom of the rare genetic eye disease Cystinosis.
Cystaran, an FDA-designated orphan drug with seven years guaranteed market exclusivity, was co-developed with the National Institutes of Health. The drug treats the accumulation of crystals of the amino acid cystine in the cornea resulting from Cystinosis, a disease that affects an estimated 2,000 people worldwide, according to the Cystinosis Research Network.
{iframe}http://www.bizjournals.com/washington/news/2012/10/04/sigma-tau-wins-fda-approval-for-eye.html?ana=e_du_pap&s=article_du&ed=2012-10-04{/iframe}